BioCryst Pharmaceuticals | BCRX - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Alnylam Pharmaceuticals USD 789.18M 555.28M 2025-12
BioCryst Pharmaceuticals USD -119.15M 268.74M 2025-12
Chugai Pharma JPY 1.89T 95.02B 2025-09
Daiichi Sankyo JPY 1.71T 57.86B 2025-12
DBV Technologies USD 52.85M 33.37M 2025-09
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 16.38B 229M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Incyte USD 5.17B 516.28M 2025-12
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
Karyopharm Therapeutics USD -269.26M 30.33M 2025-09
Neurocrine Biosciences USD 3.25B 249.5M 2025-12
Novavax USD -127.75M 28.92M 2025-12
PTC Therapeutics USD -205.31M 49.56M 2025-12
Regeneron Pharmaceuticals USD 31.26B 299.1M 2025-12
Roche Holding CHF 33.8B 758M 2025-12
Sarepta Therapeutics USD 1.14B 179.5M 2025-12
Ultragenyx Pharmaceutical USD 9.16M 142.13M 2025-09
Vertex Pharmaceuticals USD 18.67B 1.35B 2025-12